SAB BIO to Participate in Upcoming Investor Conferences
SAB Biotherapeutics, Inc. (SABS)
Company Research
Source: GlobeNewswire
MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SAb Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for autoimmune diseases, including its lead program in clinical development for delaying the progression of type 1 diabetes (T1D) in new onset Stage 3 patients, today announced that members of its management team will participate in the following investor conferences this November and December: UBS Global Healthcare ConferenceDate: November 10, 2025Time: 2:45 p.m. ETFormat: Fireside ChatLocation: West Palm Beach, FL Guggenheim Second Annual Healthcare Innovation ConferenceDate: November 12, 2025Time: 10:00 a.m. ETFormat: Fireside ChatLocation: Boston, MA8th Annual Evercore Healthcare ConferenceDate: December 2, 2025Time: 3:50 p.m. ETFormat: Fireside ChatLocation: Coral Gables, FLTo access the live webcasts of these events, as well as archived recordings, please visit the Investor Relations/Events section
Show less
Read more
Impact Snapshot
Event Time:
SABS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SABS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SABS alerts
High impacting SAB Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SABS
News
- SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SABS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreeMarketBeat
- SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.MarketBeat
- SAB Biotherapeutics (NASDAQ:SABS) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- SAB Biotherapeutics (NASDAQ:SABS) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142GlobeNewswire
SABS
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form 10-Q
- SABS's page on the SEC website